Izotropic Executes Formal Agreement with Izotropic Africa for Exclusive Distribution Throughout Africa and the GCC
British Columbia and Casablanca, Morocco--(Newsfile Corp. - July 2, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing IzoView, a dedicated breast CT imaging system for the more accurate screening and diagnosis of breast cancers, announces that, further to its
2026-07-02 8:00 AM EDT | Izotropic Corporation
OS Therapies Appoints Dr. Craig Eagle to Board of Directors
New York and Rockville, Maryland--(Newsfile Corp. - July 2, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that it has appointed Dr. Craig Eagle to the Company's Board of Directors. Dr. Eagle currently serves as the Company's Chief Medical Advisor
2026-07-02 7:30 AM EDT | OS Therapies
Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an investor fireside chat at the Piper Sandler Virtual Ophthalmology Symposium. Presentation Details Date: Thursday, July 9, 2026 Time: 2:30 p.m. Eastern Daylight Time Live Presentation: Available on Kiora's Investor Relations homepage at ir.ki
Biotechnology, Pharmaceuticals
2026-07-02 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Restart Life Sciences Reports Record-Breaking June Revenue for Holy Crap Foods as Amazon Canada Sales Surge YoY
Vancouver, British Columbia--(Newsfile Corp. - July 2, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to report its preliminary, unaudited financial results for the month of June 2026 regarding its wholly owned subsidiary, Holy Crap Foods Inc., alongside an update on internal operational infrastructure and market expansion initiatives. Following the acquisition of Holy Crap Foods Inc. on February 27, 2026, the C
Technology, Biotechnology, Health
2026-07-02 6:00 AM EDT | Restart Life Sciences Corp.
Sharp Therapeutics Announces Filing of Amended and Restated Management Information Circular and New Annual Meeting Date
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces that its annual meeting of shareholders will be held at 10:00 a.m. (Toronto time) on July 21, 2026 (the "Meeting"), having been postponed from the initial meeting date of June 30, 2026. The Company has filed an amended and restated notice of meeting (the "Amended and Restated NOM") and an a
2026-06-30 5:00 PM EDT | Sharp Therapeutics Corp.
Theralase(R) Receives Receipt for C$100 Million Base Shelf Prospectus
Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has filed and obtained a receipt for a final base shelf prospectus dated June 29, 2026 ("P
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-06-30 4:30 PM EDT | Theralase Technologies Inc.
Envoy Medical Submits First Module of Modular Premarket Approval Application to the U.S. Food and Drug Administration for Breakthrough-Designated Device
White Bear Lake, Minnesota--(Newsfile Corp. - June 30, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the submission of the first module of its Modular Premarket Approval ("PMA") application to the U.S. Food and Drug Administration ("FDA") for its FDA Breakthrough Device-designated product. The submissi
Biotechnology, Healthcare and Hospitals
2026-06-30 8:30 AM EDT | Envoy Medical, Inc.
OS Therapies Provides U.S. Regulatory Update
Type B Meeting requested to follow up on September 2025 End of Phase 2 FDA Meeting guidance on statistical methods to be used for BLA Submission Seeking to align FDA with MHRA & EMA on 3-year overall survival as approval endpoint Biomarker data submitted to FDA BEST program as surrogate clinical efficacy data Synthetic historical control arm OST-400 recruitment potentially adds comparator for BLA submission under the Accelerated Approva
2026-06-30 7:40 AM EDT | OS Therapies
Illumisoft and Capgemini Collaborate to Advance Human-Safe Far UVC Platform for Airborne Pathogen Risk Reduction in High-Occupancy Indoor Environments
Vancouver, British Columbia--(Newsfile Corp. - June 30, 2026) - Illumisoft Lighting Corp. (TSXV: UVC) ("Illumisoft" or the "Company") is developing its SaniLux 216 nanometre far ultraviolet C ("far UVC") disinfection platform to enable the safe mitigation of airborne pathogen risk in high-occupancy indoor environments where people live, work, learn, travel, and gather. Today, the Company announced that it is taking steps to accelerate the platform's development. To support the path to m
Technology, Biotechnology, Healthcare and Hospitals, Household / Consumer / Cosmetics
2026-06-30 7:00 AM EDT | Illumisoft Lighting Corporation
TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels
Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a leader in temperature-controlled medication solutions, is pleased to announce the expansion of its relationship with McKesson Medical-Surgical ("MMS"). The agreement, dated June 23, 2026, broadens the scope of collaboration to include full portfolio distribution across North America, enhanced B2B capabilities, and deeper integration into one of the la
Technology, Biotechnology, Pharmaceuticals, Health
2026-06-30 3:05 AM EDT | TempraMed Technologies Ltd.
PharmaCorp Announces Definitive Agreement to Acquire Western Canada PharmaChoice Bannered Pharmacy
Saskatoon, Saskatchewan--(Newsfile Corp. - June 29, 2026) - PHARMACORP RX INC. (TSXV: PCRX) ("PharmaCorp" or the "Corporati
Biotechnology, Pharmaceuticals, Retail
2026-06-29 7:15 AM EDT | PharmaCorp RX Inc.
American Aires Announces Letter of Intent for Proposed Sale of Assets
Toronto, Ontario--(Newsfile Corp. - June 29, 2026) - American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRF) (the "Company") announces that it has entered into a non-binding letter of intent dated June 25, 2026 (the "Letter Agreement") with an arm's-length third party purchaser (the "Purchaser") in respect of a proposed transaction pursuant to which the Purchaser would acquire certain specified assets and related rights of the Company (the "Transaction"). Under the
2026-06-29 7:00 AM EDT | American Aires Inc.
American Aires Announces Settlement Agreement with Former Officer and Director and Assignment of Patent Rights to the Company
Toronto, Ontario--(Newsfile Corp. - June 29, 2026) - American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRF) (the "Company") announces that it has entered into a settlement agreement and mutual release (the "Settlement Agreement") with its former officer and director, Dimitry Serov, and Serov Holdings Inc., pursuant to which the parties have agreed to resolve all outstanding disputes between them, including the litigation commenced by the Company in the Ontario Superior Court of Justi
2026-06-29 6:00 AM EDT | American Aires Inc.
Telo Genomics Announces Termination of Investor Relations Agreement
Vancouver, British Columbia--(Newsfile Corp. - June 26, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, announces that the investor relations consulting agreement with Sheridan Adams, LLC ("Sheridan"), as announced on March 31, 2026, has been terminated effective June 12, 2026. It was initially u
2026-06-26 8:58 PM EDT | Telo Genomics Corp.
MustGrow Biologics Corp. Announces Results of Shareholder Meeting
Saskatoon, Saskatchewan--(Newsfile Corp. - June 26, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce the results of its 2026 annual meeting of shareholders (the "Meeting") held on June 25, 2026. At the Meeting, all director nominees listed in the Company's management information circular dated May 28, 2026, were elected by shareholders as directors of the Company on a vote held by ballot.
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2026-06-26 5:00 PM EDT | MustGrow Biologics Corp.
TempraMed Signs Non-Binding LOI with National Distributor in Saudi Arabia
Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has signed a non-binding letter of intent ("LOI") dated June 16, 2026 with Rawafed Health International Company ("Rawafed"), a leading healthcare distribution company with broad reach across pharmacy networks a
Technology, Biotechnology, Pharmaceuticals, Health
2026-06-26 4:10 PM EDT | TempraMed Technologies Ltd.
Hemostemix Closes $360,000 First Tranche of Private Placement
Calgary, Alberta--(Newsfile Corp. - June 26, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed the first tranche of its previously announced non-brokered private placement of units (the "Offering"), as originally disclosed on June 17, 2026. The Company raised aggregate gross proceeds of CDN$360,000 under the first tranche through the issuance of 7,200,000 units ("Units") at
Biotechnology, Pharmaceuticals, Health
2026-06-26 8:47 AM EDT | Hemostemix Inc.
OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma
20% of OST-HER2 treated dogs survived 2-year vs. 1% in control group (p = 0.00995) Over 15,000 dogs per year diagnosed with osteosarcoma Company expects to submit U.S. Department of Agriculture meeting request to gain alignment on regulatory path towards conditional approval in the third quarter of 2026 OS Therapies reiterates plan to distribute OS Animal Health shares to shareholders OS Animal
2026-06-26 7:40 AM EDT | OS Therapies
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - June 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-26 7:00 AM EDT | Phio Pharmaceuticals Corp.
Resverlogix Announces Voting Results from the 2026 Meeting of Shareholders
Calgary, Alberta--(Newsfile Corp. - June 25, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual Meeting of Shareholders (the "Meeting") in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected Five (5) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows:
Technology, Biotechnology, Healthcare and Hospitals
2026-06-25 9:12 PM EDT | Resverlogix Corp.